Perspective Therapeutics (CATX) 10-K 28 Sep 22 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2022	Sep. 23, 2022	Dec. 31, 2021
Document Information [Line Items]
Entity Central Index Key	0000728387
Entity Registrant Name	IsoRay, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-33407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1458152
Entity Address, Address Line One	350 Hills St., Suite 106
Entity Address, City or Town	Richland
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99354
City Area Code	509
Local Phone Number	375-1202
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ISR
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 54,853,119
Entity Common Stock, Shares Outstanding		142,112,766
Auditor Firm ID	444
Auditor Name	Assure CPA, LLC
Auditor Location	Spokane, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 55,890	$ 63,828
Accounts receivable, net	1,608	2,013
Inventory	1,396	980
Prepaid expenses and other current assets	435	481
Total current assets	59,329	67,302
Non-current assets:
Property and equipment, net	1,976	1,958
Right of use asset, net	512	768
Restricted cash	182	182
Inventory, non-current	2,333	76
Other assets, net	107	130
Total assets	64,439	70,416
Current liabilities:
Accounts payable and accrued expenses	966	730
Lease liability	268	252
Accrued protocol expense	150	98
Accrued radioactive waste disposal	120	100
Accrued payroll and related taxes	509	362
Accrued vacation	253	259
Total current liabilities	2,266	1,801
Non-current liabilities:
Lease liability, non-current	256	524
Accrued payroll and related taxes, non-current	0	77
Asset retirement obligation	640	608
Total liabilities	3,162	3,010
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding	0	0
Common stock, $.001 par value; 200,000,000 shares authorized; 142,040,266 and 141,915,266 shares issued and outstanding	142	142
Additional paid-in capital	159,732	158,589
Accumulated deficit	(98,597)	(91,325)
Total stockholders' equity	61,277	67,406
Total liabilities and stockholders' equity	$ 64,439	$ 70,416

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	142,040,266	141,915,266
Common stock, shares outstanding (in shares)	142,040,266	141,915,266
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Sales, net	$ 10,795,000	$ 10,053,000	$ 9,680,000
Cost of sales	6,179,000	4,932,000	4,556,000
Gross profit	4,616,000	5,121,000	5,124,000
Operating expenses:
Research and development	2,582,000	1,427,000	1,126,000
Sales and marketing	2,804,000	2,440,000	2,976,000
General and administrative	6,621,000	4,691,000	4,571,000
Loss on equipment disposals	0	9,000	0
Change in estimate of asset retirement obligation (Note 8)	0	0	(73,000)
Total operating expenses	12,007,000	8,567,000	8,600,000
Operating loss	(7,391,000)	(3,446,000)	(3,476,000)
Non-operating income:
Interest income	119,000	59,000	30,000
Total non-operating income	119,000	59,000	30,000
Net loss	(7,272,000)	(3,387,000)	(3,446,000)
Preferred stock dividends	0	(3,000)	(11,000)
Net loss applicable to common stockholders	$ (7,272,000)	$ (3,390,000)	$ (3,457,000)
Basic and diluted loss per share (in dollars per share)	$ (0.05)	$ (0.03)	$ (0.05)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	141,987	103,841	67,601

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019	$ 0	$ 67	$ 92,105	$ (84,492)	$ 7,680
Issuance of common stock pursuant to exercise of options (in shares)		262,500			262,500
Issuance of common stock pursuant to exercise of options		$ 1	130		$ 131
Issuance of common stock pursuant to at the market offering, net (in shares)		1,247,232
Issuance of common stock pursuant to at the market offering, net		$ 1	873		874
Payment of dividend to preferred stockholders			(11)		(11)
Share-based compensation			495		495
Net loss	$ 0			(3,446)	(3,446)
Balances (in shares) at Jun. 30, 2020	59,065	68,897,779
Balances at Jun. 30, 2020	$ 0	$ 69	93,592	(87,938)	$ 5,723
Issuance of common stock pursuant to exercise of options (in shares)		970,315			970,315
Issuance of common stock pursuant to exercise of options		$ 1	533		$ 534
Issuance of common stock pursuant to at the market offering, net (in shares)		59,669,230
Issuance of common stock pursuant to at the market offering, net		$ 60	56,315		56,375
Payment of dividend to preferred stockholders			(9)		(9)
Share-based compensation			386		386
Net loss	$ 0			(3,387)	(3,387)
Conversion of preferred stock to common stock (in shares)	(59,065)	59,065
Issuance of common stock pursuant to exercise of warrants (in shares)		12,318,877
Issuance of common stock pursuant to exercise of warrants		$ 12	7,772		7,784
Balances (in shares) at Jun. 30, 2021		141,915,266
Balances at Jun. 30, 2021	$ 0	$ 142	158,589	(91,325)	$ 67,406
Issuance of common stock pursuant to exercise of options (in shares)		125,000			125,000
Issuance of common stock pursuant to exercise of options		$ 0	56		$ 56
Share-based compensation			1,087		1,087
Net loss				(7,272)	(7,272)
Balances (in shares) at Jun. 30, 2022	0	142,040,266
Balances at Jun. 30, 2022	$ 0	$ 142	$ 159,732	$ (98,597)	$ 61,277

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,272,000)	$ (3,387,000)	$ (3,446,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Lease expense	4,000	4,000	4,000
Depreciation expense	248,000	149,000	147,000
Loss on equipment disposals	0	10,000	0
Amortization of other assets	41,000	37,000	38,000
Accretion of asset retirement obligation	32,000	31,000	29,000
Change in estimate of asset retirement obligation	0	0	(73,000)
Share-based compensation	1,087,000	386,000	495,000
Changes in operating assets and liabilities:
Accounts receivable	405,000	31,000	(890,000)
Inventory	(2,673,000)	(274,000)	(97,000)
Prepaid expenses and other current assets	46,000	(56,000)	(121,000)
Accounts payable and accrued expenses	236,000	76,000	(29,000)
Accrued protocol expense	52,000	63,000	(98,000)
Accrued radioactive waste disposal	20,000	6,000	20,000
Accrued payroll and related taxes	70,000	32,000	318,000
Accrued vacation	(6,000)	55,000	62,000
Net cash used by operating activities	(7,710,000)	(2,837,000)	(3,641,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(266,000)	(381,000)	(273,000)
Additions to other assets	(18,000)	(30,000)	(14,000)
Proceeds from disposal of equipment	0	1,000	0
Net cash (used in) investing activities	(284,000)	(410,000)	(287,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	0	(9,000)	(11,000)
Proceeds from sales of common stock, pursuant to exercise of warrants	0	7,784,000	0
Proceeds from sales of common stock, pursuant to exercise of options	56,000	534,000	131,000
Net cash provided by financing activities	56,000	64,684,000	994,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	(7,938,000)	61,437,000	(2,934,000)
Cash, cash equivalents, and restricted cash beginning of year	64,010,000	2,573,000	5,507,000
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF YEAR	56,072,000	64,010,000	2,573,000
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	55,890,000	63,828,000	2,392,000
Restricted cash	182,000	182,000	181,000
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF YEAR	56,072,000	64,010,000	2,573,000
Non-cash investing and financing activities:
Recognition of operating lease liability and right of use asset	0	0	1,228,000
Underwritten Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of common stock, pursuant to underwritten offering, net	0	56,375,000	0
At the Market Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of common stock, pursuant to underwritten offering, net	$ 0	$ 0	$ 874,000

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization Isoray, Inc. was incorporated in Minnesota in 1983. July 28, 2005, December 2018, June 15, 2004 October 1, 2004 two 1998. Isoray International LLC (International), a Washington limited liability company, was formed on November 27, 2007

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation. Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three Investments Investments in debt securities with original maturities greater than three one one June 30, 2022, no Accounts Receivable Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries. Inventory Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a first first The cost of materials and production costs contained in inventory that are not no Property and Equipment Property and Equipment is capitalized and carried at cost less accumulated depreciation. Depreciation expense is recorded to cost of sales and operating expenses. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment (in years) 3 to 7 Office equipment (in years) 2 to 10 Furniture and fixtures (in years) 2 to 10 Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Property and equipment that is acquired but not no Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is not Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment. Prepaid Expenses and Other Assets Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value. Asset Retirement Obligation The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the leased assets are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets. Adjustments and changes to either the timing or amount of the original present value estimate underlying the obligation are made in the period incurred. Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At June 30, 2022 2021, Fair Value Measurement When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 2 3 no At June 30, 2022 2021, no not Revenue Recognition The Company recognizes revenue based on the five 606, Revenue from Contracts with Customers 1 2 3 4 5 not no 17. Shipping and Handling Costs Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in revenue. Share-Based Compensation The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur. Research and Development Costs Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not Advertising and Marketing Costs Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands) For the Years Ended June 30, 2022 2021 2020 Advertising and marketing costs expensed (including tradeshows) $ 129 $ 84 $ 141 At June 30, 2022 2021 Prepaid marketing expenses deferred until event occurs $ 25 $ 21 Legal Contingencies The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third not Income Taxes Income taxes are accounted for under the liability method in accordance with ASC 740, Income Taxes not not not two 1 not 2 not 50% Leases The Company accounts for its leases under ASC 842, Leases Income (Loss) Per Common Share Basic earnings per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding, and does not Securities that could be dilutive in the future are as follows: June 30, 2022 2021 2020 Preferred stock - - 59,065 Common stock warrants 2,645,738 2,645,738 6,080,000 Common stock options 6,914,025 4,514,660 5,497,505 Total potential dilutive securities 9,559,763 7,160,398 11,636,570 Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility and estimated lives of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements. Recent Accounting Pronouncements Accounting Standards Updates to Become Effective in Future Periods Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Inventory

Note 3 - Inventory	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory Inventory consisted of the following (in thousands): June 30, Inventory, current 2022 2021 Raw materials $ 911 $ 645 Work in process 462 286 Finished goods 23 49 Total inventory, current $ 1,396 $ 980 June 30, Inventory, non-current 2022 2021 Enriched barium, non-current $ 2,269 $ - Raw materials, non-current 64 76 Total inventory, non-current $ 2,333 $ 76 Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 December 13, 2021, one August 2017 December 31, 2022. On September 9, 2021, September 2021 6,000 September 2021, 131, twelve June 30, 2022, 915 131 June 30, 2022, 3,111 1,040 twelve 2,071 June 30, 2023. 1,040 no third 131 On March 31, 2022, two first 5,746.6 second 6,310.4 June 30, 2022, 6,000 131. no 131, third 131

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Other Current Assets [Text Block]	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): June 30, 2022 2021 Prepaid insurance $ 122 $ 107 Other prepaid expenses 269 315 Other current assets 27 27 Other receivables 17 32 Total prepaid expenses and other current assets $ 435 $ 481

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property & Equipment Property & equipment consisted of the following (in thousands): June 30, 2022 2022 2021 Land $ 366 $ 366 Equipment 4,438 4,202 Leasehold improvements 4,143 4,143 Other 1 525 495 Property and equipment 9,472 9,206 Less accumulated depreciation (7,496 ) (7,248 ) Property and equipment, net $ 1,976 $ 1,958 1. Plant and equipment, not June 30, 2022 2021 2017. three five

Note 6 - Restricted Cash

Note 6 - Restricted Cash	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	6. Restricted Cash The Washington Department of Health requires the Company to provide collateral for the decommissioning of its facility. To satisfy this requirement, the Company has a bank account with a balance of $182,000. The account is termed restricted cash and classified as a long-term asset as the Company does not July 2019 April 30, 2026.

Note 7 - Other Assets, Net

Note 7 - Other Assets, Net	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Other Assets Disclosure [Text Block]	7. Other Assets, net Other assets, net of accumulated amortization consisted of the following (in thousands): June 30, 2022 2021 Website development $ 90 $ 90 Licenses 520 520 Patents and trademarks 378 378 Total Other Assets 988 988 Less: Accumulated Amortization (881 ) (858 ) $ 107 $ 130 Year Ended June 30, 2022 2021 2020 Amortization expense on website development $ 7 $ 7 $ 8 Amortization expense on licenses 18 14 14 Amortization expense on patents and trademarks 16 16 16 Total amortization expense $ 41 $ 37 $ 38 Future amortization is expected to be as follows (in thousands): Year ended June 30, 2023 $ 42 2024 23 2025 22 2026 10 2027 10 Thereafter - $ 107

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in September 2007. 842 July 1, 2019, April 2024 $1.2 not June 30, 2022 June 30, 2022 ( Year Ending June 30, 2023 292 2024 264 Total 556 Less: Imputed interest (32 ) Total Lease Liability 524 Less current portion (268 ) Non-current Lease Liability $ 256 For the fiscal years ended June 30, 2022, 2021, 2020 June 31, 2022, 2021 2020 Asset Retirement Obligation The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. The following table presents the change in the ARO (in thousands): Year ended June 30, 2022 2021 Beginning balance $ 608 $ 577 Accretion of discount 32 31 Ending Balance $ 640 $ 608 In July 2019, five $73,000.

Note 9 - Share-Based Compensati

Note 9 - Share-Based Compensation	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. Share-Based Compensation The Company currently provides share-based compensation under two ■ 2017 2017 ■ 2020 2020 Options granted prior to fiscal 2017 The Company’s stockholders approved the 2017 “2017 June 2017. 2017 On December 7, 2021, 2020 2020 2020 2020 2020 may The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no not The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows: For the Year Ended June 30, 2022 2021 2020 Weighted average fair value $0.55 $0.86 $0.39 Options issued 3,269,100 400,000 1,330,000 Exercise price $0.28 to $0.79 $0.64 to $1.66 $0.32 to $0.61 Expected term (in years) 5 5 5 Risk-free rate 0.73% to 3.24% 0.22% to 0.94% .33% to 1.80% Volatility 99% - 100% 83% - 100% 83% - 89% The following table presents the share-based compensation expense (in thousands): For the Year Ended June 30, 2022 2021 2020 Cost of sales $ 80 $ 30 $ 21 Research and development expense 244 104 111 Sales and marketing expense 47 49 125 General and administrative expense 716 203 238 Total share-based compensation $ 1,087 $ 386 $ 495 The total value of the stock options awards is expensed ratably over the vesting period of the employees receiving the awards. As of June 30, 2022, A summary of stock option information within the Company’s share-based compensation plans during the fiscal years is presented below: Options Outstanding Price (a) Life (b) Value (c) Balance at June 30, 2019 4,645,315 $ 0.64 7.95 $ 1 Granted (d) 1,330,000 0.61 Expired (192,810 ) 1.33 Forfeited (22,500 ) 0.42 Exercised (262,500 ) 0.49 Balance at June 30, 2020 5,497,505 $ 0.62 7.85 $ 233 Granted (d) 400,000 1.18 Expired (149,405 ) 1.07 Forfeited (263,125 ) 0.53 Exercised (970,315 ) 0.55 Balance at June 30, 2021 4,514,660 $ 0.67 7.27 $ 984 Granted (d) 3,269,100 0.75 Expired (256,060 ) 0.84 Forfeited (488,675 ) 0.79 Exercised (125,000 ) 0.45 Balance at June 30, 2022 6,914,025 $ 0.70 7.43 $ 2 Vested and expected to vest at June 30, 2022 6,914,025 $ 0.70 7.43 $ 2 Exercisable at June 30, 2022 4,432,121 $ 0.66 6.58 $ 1 (a) Weighted average exercise price per share. (b) Weighted average remaining contractual life. (c) Aggregate intrinsic value (in thousands). (d) All options granted had exercise prices equal to or greater than the ending closing market price of the Company’s common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to five For the Year Ended June 30, 2022 2021 2020 Aggregate intrinsic value of options exercised (in thousands) $ 3 $ 770 $ 83 The Company’s current policy is to issue new shares to satisfy option exercises.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity The authorized capital structure of the Company consists of $.001 $.001 Common Stock On January 23, 2020, 3 February 4, 2020, March 31, 2020, June 30, 2020, 2021 2022. October 19, 2020, On October 22, 2020, five On February 8, 2021, February 8, 2021 During Fiscal 2021, During Fiscal 2022, Preferred Stock The Company’s Certificate of Incorporation authorizes 7,000,000 shares of $0.001 June 30, 2022 no June 30, 2022. Series B 59,065 shares of Series B preferred stock automatically converted into 59,065 shares of common stock as a result of the October 22, 2020 December 8, 2020, October 22, 2020. December 31, 2020. June 30, 2022 2021, zero $0 $0 Warrants During the year ended June 30, 2021, October 22, 2020. Warrants issued 9,134,615 Exercise price $0.57 Expected term (in years) 5 Risk-free rate 0.38% Volatility 85% During the year ended June 30, 2022 not The following table summarizes the activity of all stock warrants and weighted average exercise prices. Warrants Price (a) Balance at June 30, 2019 6,080,000 $ 0.75 Balance at June 30, 2020 6,080,000 $ 0.75 Warrants issued 9,134,615 0.57 Warrants exercised (12,318,877 ) 0.63 Warrants expired (250,000 ) 0.54 Balance at June 30, 2021 2,645,738 $ 0.70 Warrants issued - - Warrants exercised - - Warrants expired - - Balance at June 30, 2022 2,645,738 $ 0.70 (a) Weighted average exercise price per share. As of June 30, 2022, July 10, 2023, January 11, 2024, October 22, 2025.

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Due to net losses, the Company did not June 30, 2022, 2021 2020. The significant deferred tax components using a federal income tax rate of 21% June 30, 2022 2021 As of June 30, 2022 2021 Fixed assets $ 9 $ 55 Share-based compensation 525 563 Other accruals 106 49 Asset retirement obligation 134 128 Research credit carryforwards 389 277 Other 7 6 Net operating loss carryforwards 17,904 16,568 Total deferred tax assets 19,074 17,646 Valuation allowance (19,074 ) (17,646 ) Total $ - $ - As management of the Company cannot determine that it is more likely than not June 30, 2022 2021. The Company has federal net operating loss carryforwards of approximately $67.5 million on June 30, 2022 2025 2038. June 30, 2022 80% not The Company has a research credit carryforward of approximately $0.4 million on June 30, 2022 2037 2042. The Company’s statutory rate reconciliation is as follows (in thousands): For the year ended June 30, 2022 2021 2020 U.S. federal statutory income tax rate 21 % 21 % 21 % Expected income tax benefit $ (1,522 ) $ (711 ) $ (724 ) Meals and entertainment 14 6 8 Non-deductible penalties 25 22 24 Change in estimate (9 ) 28 (58 ) Incentive stock options 126 48 - Research credit (62 ) (52 ) 11 Change in valuation allowance 1,428 659 739 Income tax expense (benefit) $ - $ - $ - The Company has reviewed the tax positions taken and concluded that it does not Currently, tax years 2020 2022 2020

Note 12 - 401(k) and Profit Sha

Note 12 - 401(k) and Profit Sharing Plan	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Retirement Benefits [Text Block]	12. 401 The Company has a 401 2007, 401 401 not 401 January 1, 2022, 401 first third 2023 401 January 1, 2022 December 31, 2022. June 30, 2022 2021

Note 13 - Distribution Agreemen

Note 13 - Distribution Agreements	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Agreements Disclosure [Text Block]	13. Distribution Agreements On July 14, 2017, one two one July 2020. September 22, 2020, one two one 2020, three 131 August 1, 2016. one two one August 1, 2019 not not 2019,

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Isotope Purchase Agreement On August 26, 2020, August 2020 December 2021 131 February 10, 2021, March 18, 2021, 131 March 18, 2021 March 31, 2023. July 29, 2021, 131 August 19, 2021, 131 April 11, 2022 , 131 April 11, 2022 , 131 .

Note 15 - Concentrations of Cre

Note 15 - Concentrations of Credit and Other Risks	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	15. Concentrations of Credit and Other Risks The Company’s financial instruments that were exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and accounts receivable. The Company’s cash and cash equivalents were maintained with high-quality financial institutions at June 30, 2022 2021, June 30, 2022 2021, no The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. At both June 30, 2022 2021, Inventories Most components used in the Company’s product are purchased from outside sources. Certain components are purchased from single suppliers. The failure of any such supplier to meet its commitment on schedule could have a material adverse effect on the Company’s business, operating results and financial condition. If a sole-source supplier were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company’s production could be delayed. Such delays could have a material adverse effect on the Company’s business, operating results and financial condition. Sanctions placed on financial transactions with Russian banking institutions may 131

Note 16 - Quarterly Financial D

Note 16 - Quarterly Financial Data (unaudited)	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Quarterly Financial Information [Text Block]	16 . Quarterly Financial Data (unaudited) The following table provides the selected quarterly financial data for fiscal years 2022 2021 Quarters ended September 30, December 31, March 31, June 30, 2021 2021 2022 2022 Net revenue $ 2,564 $ 2,816 $ 2,910 $ 2,505 Gross profit $ 1,029 $ 1,220 $ 1,441 $ 926 Net loss $ (2,243 ) $ (1,604 ) $ (1,347 ) $ (2,078 ) Net loss per share – basic and diluted $ (0.02 ) $ (0.01 ) $ (0.01 ) $ (0.01 ) Shares used in basic and diluted per share calculation 141,915 141,955 142,040 142,040 Quarters ended September 30, December 31, March 31, June 30, 2020 2020 2021 2021 Net revenue $ 2,384 $ 2,359 $ 2,600 $ 2,710 Gross profit/(loss) $ 1,246 $ 1,167 $ 1,362 $ 1,346 Net loss $ (713 ) $ (868 ) $ (745 ) $ (1,061 ) Net loss per share – basic and diluted $ (0.01 ) $ (0.01 ) $ (0.01 ) $ (0.01 ) Shares used in basic and diluted per share calculation 68,898 83,047 122,566 141,673 1. Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may

Note 17 - Contracts With Custom

Note 17 - Contracts With Customers	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	17. Contracts with Customers We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do not no not not not not not Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. During the fiscal year 2022 2021 2020, 2021 2020 2022, not 2021 2020. Contract Balances We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not not Returns Generally, we allow returns if not may Commissions and Contract Costs We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not Concentration of Customers The following are the Company’s top customers, facilities or physician practices that utilize multiple surgical facilities shown as a percentage of total sales for the twelve June 30, 2022: Year ended June 30, Facility 2022 % of total revenue 2021 % of total revenue 2020 % of total revenue El Camino, Los Gatos, & other facilities (1) 27.9 % 25.3 % 26.8 % GT Medical Technologies 14.2 % 11.3 % <10.0 % ( 1 The head of the single largest physician practice also serves as the Company’s medical director. As the medical director, this physician advises the Company Board of Directors and management, provides technical advice related to product development and research and development, and provides internal training to the Company sales staff and professional training to our sales staff and to other physicians. None 10% September 20, 2022, The following is the Company’s top customer shown as a percentage of total accounts receivable for the twelve June 30, 2022: Year ended June 30, Facility 2022 % of total accounts receivable 2021 % of total accounts receivable 2020 % of total accounts receivable GT Medical Technologies <10.0 % 10.2 % <10.0 %

Note 18 - Related Parties

Note 18 - Related Parties	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	18. Related Parties During fiscal year 2022, not four no

Note 19 - Subsequent Events

Note 19 - Subsequent Events	12 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	19. Subsequent Events At the end of July 2022, one second August not August 2022 September 2022 not 131 not no 131. September 7, 2022, On September 27, 2022, no Upon the closing of the Merger, Isoray will increase the size of its Board of Directors from four members to not one one Consummation of the Merger is subject to the satisfaction or waiver of various closing conditions, including: (i) performance in all respects by each party of its covenants and agreements, (ii) Isoray and Viewpoint each obtaining approval by its stockholders of the Merger and related matters, (iii) any necessary consents or approvals by governmental and regulatory authorities and non-governmental third no The Merger Agreement contains certain restrictions on the conduct of the Company’s and Viewpoint’s respective businesses between the date of signing the Merger Agreement and the earlier of the closing of the Merger or the termination of the Merger Agreement. During such period, Isoray and Viewpoint each must conduct its business in the ordinary course and consistent with past practices in all material respects and may not 8 September 28, 2022.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three
Investment, Policy [Policy Text Block]	Investments Investments in debt securities with original maturities greater than three one one June 30, 2022, no
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.
Inventory, Policy [Policy Text Block]	Inventory Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a first first The cost of materials and production costs contained in inventory that are not no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and Equipment is capitalized and carried at cost less accumulated depreciation. Depreciation expense is recorded to cost of sales and operating expenses. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment (in years) 3 to 7 Office equipment (in years) 2 to 10 Furniture and fixtures (in years) 2 to 10 Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Property and equipment that is acquired but not no Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is not Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.
Other Assets [Policy Text Block]	Prepaid Expenses and Other Assets Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.
Asset Retirement Obligation [Policy Text Block]	Asset Retirement Obligation The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the leased assets are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets. Adjustments and changes to either the timing or amount of the original present value estimate underlying the obligation are made in the period incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At June 30, 2022 2021,
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 2 3 no At June 30, 2022 2021, no not
Revenue [Policy Text Block]	Revenue Recognition The Company recognizes revenue based on the five 606, Revenue from Contracts with Customers 1 2 3 4 5 not no 17.
Shipping and Handling Cost [Policy Text Block]	Shipping and Handling Costs Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in revenue.
Share-Based Payment Arrangement [Policy Text Block]	Share-Based Compensation The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not
Advertising Cost [Policy Text Block]	Advertising and Marketing Costs Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands) For the Years Ended June 30, 2022 2021 2020 Advertising and marketing costs expensed (including tradeshows) $ 129 $ 84 $ 141 At June 30, 2022 2021 Prepaid marketing expenses deferred until event occurs $ 25 $ 21
Commitments and Contingencies, Policy [Policy Text Block]	Legal Contingencies The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third not
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the liability method in accordance with ASC 740, Income Taxes not not not two 1 not 2 not 50%
Lessee, Leases [Policy Text Block]	Leases The Company accounts for its leases under ASC 842, Leases
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Common Share Basic earnings per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding, and does not Securities that could be dilutive in the future are as follows: June 30, 2022 2021 2020 Preferred stock - - 59,065 Common stock warrants 2,645,738 2,645,738 6,080,000 Common stock options 6,914,025 4,514,660 5,497,505 Total potential dilutive securities 9,559,763 7,160,398 11,636,570
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility and estimated lives of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Accounting Standards Updates to Become Effective in Future Periods Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Estimated Useful Lives of Assets [Table Text Block]	Production equipment (in years) 3 to 7 Office equipment (in years) 2 to 10 Furniture and fixtures (in years) 2 to 10
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	For the Years Ended June 30, 2022 2021 2020 Advertising and marketing costs expensed (including tradeshows) $ 129 $ 84 $ 141 At June 30, 2022 2021 Prepaid marketing expenses deferred until event occurs $ 25 $ 21
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2022 2021 2020 Preferred stock - - 59,065 Common stock warrants 2,645,738 2,645,738 6,080,000 Common stock options 6,914,025 4,514,660 5,497,505 Total potential dilutive securities 9,559,763 7,160,398 11,636,570

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, Inventory, current 2022 2021 Raw materials $ 911 $ 645 Work in process 462 286 Finished goods 23 49 Total inventory, current $ 1,396 $ 980
Schedule of Inventory, Noncurrent [Table Text Block]	June 30, Inventory, non-current 2022 2021 Enriched barium, non-current $ 2,269 $ - Raw materials, non-current 64 76 Total inventory, non-current $ 2,333 $ 76

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2022 2021 Prepaid insurance $ 122 $ 107 Other prepaid expenses 269 315 Other current assets 27 27 Other receivables 17 32 Total prepaid expenses and other current assets $ 435 $ 481

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2022 2022 2021 Land $ 366 $ 366 Equipment 4,438 4,202 Leasehold improvements 4,143 4,143 Other 1 525 495 Property and equipment 9,472 9,206 Less accumulated depreciation (7,496 ) (7,248 ) Property and equipment, net $ 1,976 $ 1,958

Note 7 - Other Assets, Net (Tab

Note 7 - Other Assets, Net (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Other Assets [Table Text Block]	June 30, 2022 2021 Website development $ 90 $ 90 Licenses 520 520 Patents and trademarks 378 378 Total Other Assets 988 988 Less: Accumulated Amortization (881 ) (858 ) $ 107 $ 130 Year Ended June 30, 2022 2021 2020 Amortization expense on website development $ 7 $ 7 $ 8 Amortization expense on licenses 18 14 14 Amortization expense on patents and trademarks 16 16 16 Total amortization expense $ 41 $ 37 $ 38
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ended June 30, 2023 $ 42 2024 23 2025 22 2026 10 2027 10 Thereafter - $ 107

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending June 30, 2023 292 2024 264 Total 556 Less: Imputed interest (32 ) Total Lease Liability 524 Less current portion (268 ) Non-current Lease Liability $ 256
Schedule of Change in Asset Retirement Obligation [Table Text Block]	Year ended June 30, 2022 2021 Beginning balance $ 608 $ 577 Accretion of discount 32 31 Ending Balance $ 640 $ 608

Note 9 - Share-Based Compensa_2

Note 9 - Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Year Ended June 30, 2022 2021 2020 Weighted average fair value $0.55 $0.86 $0.39 Options issued 3,269,100 400,000 1,330,000 Exercise price $0.28 to $0.79 $0.64 to $1.66 $0.32 to $0.61 Expected term (in years) 5 5 5 Risk-free rate 0.73% to 3.24% 0.22% to 0.94% .33% to 1.80% Volatility 99% - 100% 83% - 100% 83% - 89%
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	For the Year Ended June 30, 2022 2021 2020 Cost of sales $ 80 $ 30 $ 21 Research and development expense 244 104 111 Sales and marketing expense 47 49 125 General and administrative expense 716 203 238 Total share-based compensation $ 1,087 $ 386 $ 495
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Options Outstanding Price (a) Life (b) Value (c) Balance at June 30, 2019 4,645,315 $ 0.64 7.95 $ 1 Granted (d) 1,330,000 0.61 Expired (192,810 ) 1.33 Forfeited (22,500 ) 0.42 Exercised (262,500 ) 0.49 Balance at June 30, 2020 5,497,505 $ 0.62 7.85 $ 233 Granted (d) 400,000 1.18 Expired (149,405 ) 1.07 Forfeited (263,125 ) 0.53 Exercised (970,315 ) 0.55 Balance at June 30, 2021 4,514,660 $ 0.67 7.27 $ 984 Granted (d) 3,269,100 0.75 Expired (256,060 ) 0.84 Forfeited (488,675 ) 0.79 Exercised (125,000 ) 0.45 Balance at June 30, 2022 6,914,025 $ 0.70 7.43 $ 2 Vested and expected to vest at June 30, 2022 6,914,025 $ 0.70 7.43 $ 2 Exercisable at June 30, 2022 4,432,121 $ 0.66 6.58 $ 1 For the Year Ended June 30, 2022 2021 2020 Aggregate intrinsic value of options exercised (in thousands) $ 3 $ 770 $ 83

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	Warrants issued 9,134,615 Exercise price $0.57 Expected term (in years) 5 Risk-free rate 0.38% Volatility 85%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Price (a) Balance at June 30, 2019 6,080,000 $ 0.75 Balance at June 30, 2020 6,080,000 $ 0.75 Warrants issued 9,134,615 0.57 Warrants exercised (12,318,877 ) 0.63 Warrants expired (250,000 ) 0.54 Balance at June 30, 2021 2,645,738 $ 0.70 Warrants issued - - Warrants exercised - - Warrants expired - - Balance at June 30, 2022 2,645,738 $ 0.70

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of June 30, 2022 2021 Fixed assets $ 9 $ 55 Share-based compensation 525 563 Other accruals 106 49 Asset retirement obligation 134 128 Research credit carryforwards 389 277 Other 7 6 Net operating loss carryforwards 17,904 16,568 Total deferred tax assets 19,074 17,646 Valuation allowance (19,074 ) (17,646 ) Total $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the year ended June 30, 2022 2021 2020 U.S. federal statutory income tax rate 21 % 21 % 21 % Expected income tax benefit $ (1,522 ) $ (711 ) $ (724 ) Meals and entertainment 14 6 8 Non-deductible penalties 25 22 24 Change in estimate (9 ) 28 (58 ) Incentive stock options 126 48 - Research credit (62 ) (52 ) 11 Change in valuation allowance 1,428 659 739 Income tax expense (benefit) $ - $ - $ -

Note 16 - Quarterly Financial_2

Note 16 - Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Quarterly Financial Information [Table Text Block]	Quarters ended September 30, December 31, March 31, June 30, 2021 2021 2022 2022 Net revenue $ 2,564 $ 2,816 $ 2,910 $ 2,505 Gross profit $ 1,029 $ 1,220 $ 1,441 $ 926 Net loss $ (2,243 ) $ (1,604 ) $ (1,347 ) $ (2,078 ) Net loss per share – basic and diluted $ (0.02 ) $ (0.01 ) $ (0.01 ) $ (0.01 ) Shares used in basic and diluted per share calculation 141,915 141,955 142,040 142,040 Quarters ended September 30, December 31, March 31, June 30, 2020 2020 2021 2021 Net revenue $ 2,384 $ 2,359 $ 2,600 $ 2,710 Gross profit/(loss) $ 1,246 $ 1,167 $ 1,362 $ 1,346 Net loss $ (713 ) $ (868 ) $ (745 ) $ (1,061 ) Net loss per share – basic and diluted $ (0.01 ) $ (0.01 ) $ (0.01 ) $ (0.01 ) Shares used in basic and diluted per share calculation 68,898 83,047 122,566 141,673

Note 17 - Contracts With Cust_2

Note 17 - Contracts With Customers (Tables)	12 Months Ended
	Jun. 30, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Year ended June 30, Facility 2022 % of total revenue 2021 % of total revenue 2020 % of total revenue El Camino, Los Gatos, & other facilities (1) 27.9 % 25.3 % 26.8 % GT Medical Technologies 14.2 % 11.3 % <10.0 % Year ended June 30, Facility 2022 % of total accounts receivable 2021 % of total accounts receivable 2020 % of total accounts receivable GT Medical Technologies <10.0 % 10.2 % <10.0 %

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Jun. 30, 2022
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	2 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	10 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Advertising and marketing costs expensed (including tradeshows)	$ 129	$ 84	$ 141
Prepaid marketing expenses deferred until event occurs	$ 25	$ 21

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities (in shares)	9,559,763	7,160,398	11,636,570
Preferred Stocks [Member]
Antidilutive Securities (in shares)	0	0	59,065
Warrant [Member]
Antidilutive Securities (in shares)	2,645,738	2,645,738	6,080,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	6,914,025	4,514,660	5,497,505

Note 3 - Inventory (Details Tex

Note 3 - Inventory (Details Textual) - Enriched Barium Inventory [Member] - USD ($)	Sep. 09, 2021	Mar. 31, 2022
Payments to Suppliers	$ 720,000
Purchase Agreement One [Member]
Agreements, Payable to Suppliers		$ 876,357
Purchase Agreement Two [Member]
Agreements, Payable to Suppliers		$ 957,608

Note 3 - Inventory - Current In

Note 3 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Raw materials	$ 911	$ 645
Work in process	462	286
Finished goods	23	49
Total inventory, current	$ 1,396	$ 980

Note 3 - Inventory - Noncurrent

Note 3 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Total inventory, non-current	$ 2,333	$ 76
Enriched Barium Inventory [Member]
Total inventory, non-current	2,269	0
Raw Materials [Member]
Total inventory, non-current	$ 64	$ 76

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Prepaid insurance	$ 122	$ 107
Other prepaid expenses	269	315
Other current assets	27	27
Other receivables	17	32
Total prepaid expenses and other current assets	$ 435	$ 481

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Depreciation, Total	$ 248,000	$ 149,000	$ 147,000
Other [Member]
Depreciation, Total	0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000	$ 207,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Jun. 30, 2022	Jun. 30, 2021
Property and equipment, gross		$ 9,472	$ 9,206
Less accumulated depreciation		(7,496)	(7,248)
Property and equipment, net		1,976	1,958
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		4,438	4,202
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,143
Other [Member]
Property and equipment, gross	[1]	$ 525	$ 495
[1]Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at June 30, 2022 and 2021 are costs associated with advance planning and design work on the Company’s new production facility of approximately $207,000. The advance planning and design work was primarily incurred in fiscal year 2017. The new production facility is currently on hold as the Company has sufficient production capacity to meet future demands and while the Company focuses its resources on revenue growth. It is anticipated that the Company will continue work on the new production facility process in the next three to five years.

Note 6 - Restricted Cash (Detai

Note 6 - Restricted Cash (Details Textual)	Jun. 30, 2022 USD ($)
Restricted Cash and Cash Equivalents, Total	$ 182,000

Note 7 - Other Assets, Net - Ot

Note 7 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Finite-Lived Intangible Assets, Gross	$ 988	$ 988
Less: Accumulated Amortization	(881)	(858)
Other assets, net	107	130
Amortization of Intangible Assets	41	37	$ 38
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets, Gross	90	90
Amortization of Intangible Assets	7	7	8
Licensing Agreements [Member]
Finite-Lived Intangible Assets, Gross	520	520
Amortization of Intangible Assets	18	14	14
Intellectual Property [Member]
Finite-Lived Intangible Assets, Gross	378	378
Amortization of Intangible Assets	$ 16	$ 16	$ 16

Note 7 - Other Assets, Net - Fu

Note 7 - Other Assets, Net - Future Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Year ended June 30, 2023	$ 42
2024	23
2025	22
2026	10
2027	10
Thereafter	0
Other assets, net	$ 107	$ 130

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended		12 Months Ended
	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jul. 01, 2019 USD ($)
Operating Lease, Right-of-Use Asset			$ 512,000	$ 768,000
Operating Lease, Weighted Average Discount Rate, Percent			6%
Operating Lease, Weighted Average Remaining Lease Term (Year)			1 year 9 months 18 days
Operating Lease, Expense			$ 312,000	304,000	$ 294,000
Lessee, Operating Lease, Renewal Term (Year)		5 years
ARO Original Obligation Amount		$ 704,000
ARO Discount Amount Interest Rate		5.10%
Asset Retirement Obligation, After Adjustment		$ 555,000
Gain (Loss) on Change in ARO Estimate		$ 73,000	0	0	73,000
Cost of Sales [Member]
Operating Lease, Expense			198,000	195,000	187,000
General and Administrative Expense [Member]
Operating Lease, Expense			$ 114,000	$ 109,000	$ 107,000
Forecast [Member]
Termination of Lease, Penalty	$ 20,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 1,200,000
Operating Lease, Weighted Average Discount Rate, Percent						6%
Applied Process Engineering Laboratory [Member]
Area of Real Estate Property (Square Foot) | ft²			15,000

Note 8 - Leases - Future Operat

Note 8 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
2023	$ 292
2024	264
Total	556
Less: Imputed interest	(32)
Total Lease Liability	524
Less current portion	(268)	$ (252)
Non-current Lease Liability	$ 256	$ 524

Note 8 - Leases - Asset Retirem

Note 8 - Leases - Asset Retirement Obligation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Beginning balance	$ 608	$ 577
Accretion of discount	32	31	$ 29
Ending Balance	$ 640	$ 608	$ 577

Note 9 - Share-Based Compensa_3

Note 9 - Share-Based Compensation (Details Textual) - USD ($)		12 Months Ended
	Dec. 07, 2021	Jun. 30, 2022	Jun. 30, 2017
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 966,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		11 months 15 days
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		5 years
The 2017 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			4,000,000
Amended 2020 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	16,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	10,000,000

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Assumptions (Details) - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Weighted average fair value (in dollars per share)	$ 0.55	$ 0.86	$ 0.39
Options issued (in shares)	3,269,100	400,000	1,330,000
Expected term (in years) (Year)	5 years	5 years	5 years
Minimum [Member]
Exercise price (in dollars per share)	$ 0.28	$ 0.64	$ 0.32
Risk-free rate	0.73%	0.22%	33%
Volatility	99%	83%	83%
Maximum [Member]
Exercise price (in dollars per share)	$ 0.79	$ 1.66	$ 0.61
Risk-free rate	3.24%	0.94%	1.80%
Volatility	100%	100%	89%

Note 9 - Share-Based Compensa_5

Note 9 - Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Share-based compensation	$ 1,087	$ 386	$ 495
Cost of Sales [Member]
Share-based compensation	80	30	21
Research and Development Expense [Member]
Share-based compensation	244	104	111
Selling and Marketing Expense [Member]
Share-based compensation	47	49	125
General and Administrative Expense [Member]
Share-based compensation	$ 716	$ 203	$ 238

Note 9 - Share-Based Compensa_6

Note 9 - Share-Based Compensation - Summary of Stock Option (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021		Jun. 30, 2020		Jun. 30, 2019
Balance, Options (in shares)		4,514,660	5,497,505		4,645,315
Balance, Price (in dollars per share)	[1]	$ 0.67	$ 0.62		$ 0.64
Balance, Life (Year)	[2]	7 years 5 months 4 days	7 years 3 months 7 days		7 years 10 months 6 days		7 years 11 months 12 days
Balance, Value	[3]	$ 2	$ 984		$ 233		$ 1
Granted, Options (in shares)	[4]	3,269,100	400,000		1,330,000
Granted, Price (in dollars per share)	[1],[4]	$ 0.75	$ 1.18		$ 0.61
Expired, Options (in shares)		(256,060)	(149,405)		(192,810)
Expired, Price (in dollars per share)		$ 0.84	$ 1.07	[1]	$ 1.33	[1]
Forfeited, Options (in shares)		(488,675)	(263,125)		(22,500)
Forfeited, Price (in dollars per share)		$ 0.79	$ 0.53	[1]	$ 0.42	[1]
Exercised, Options (in shares)		(125,000)	(970,315)		(262,500)
Exercised, Price (in dollars per share)	[1]	$ 0.45	$ 0.55		$ 0.49
Balance, Options (in shares)		6,914,025	4,514,660		5,497,505		4,645,315
Balance, Price (in dollars per share)	[1]	$ 0.70	$ 0.67		$ 0.62		$ 0.64
Vested and expected to vest, Options (in shares)		6,914,025
Vested and expected to vest, Price (in dollars per share)	[1]	$ 0.70
Vested and expected to vest, Life (Year)	[2]	7 years 5 months 4 days
Vested and expected to vest, Value	[3]	$ 2
Exercisable, Options (in shares)		4,432,121
Exercisable, Price (in dollars per share)	[1]	$ 0.66
Exercisable, Life (Year)	[2]	6 years 6 months 29 days
Exercisable, Value	[3]	$ 1
Aggregate intrinsic value of options exercised (in thousands)		$ 3	$ 770		$ 83
[1]Weighted average exercise price per share.[2]Weighted average remaining contractual life.[3]Aggregate intrinsic value (in thousands).[4]All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to five years.

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($)					12 Months Ended
		Feb. 08, 2021	Oct. 22, 2020	Mar. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Jan. 23, 2020	Jun. 30, 2019
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.001	$ 0.001
Common Stock, Par or Stated Value Per Share (in dollars per share)					0.001	0.001
Maximum Amount of Equity Securities That Could be Registered									$ 80,000,000
Stock Issued During Period, Shares, New Issues (in shares)		36,000,000	18,269,230
Shares Issued, Price Per Share (in dollars per share)		$ 1.25	$ 0.52
Proceeds from Issuance of Common Stock		$ 51,750,000	$ 9,500,000
Proceeds from Issuance of Common Stock, Net of Issuance Costs		47,904,000	$ 8,471,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	[1]				$ 0.70	$ 0.70	$ 0.75			$ 0.75
Proceeds from Warrant Exercises					$ 0	$ 7,784,000	$ 0
Class of Warrant or Right, Exercised During Period (in shares)					0	12,318,877
Proceeds from Stock Options Exercised					$ 56,000	$ 534,000	$ 131,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)					125,000	970,315	262,500
Preferred Stock, Shares Authorized (in shares)					7,000,000	7,000,000
Class of Warrant or Right, Issued During Period (in shares)					0	9,134,615
Class of Warrant or Right, Outstanding (in shares)					2,645,738	2,645,738	6,080,000			6,080,000
Series B Preferred Stock Converted into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)			59,065
Conversion of Stock, Shares Issued (in shares)			59,065
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)					0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)					5,000,000	5,000,000
Preferred Stock, Shares Issued, Total (in shares)					0	0
Cumulative Dividends								$ 9,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0
Preferred Stock, Amount of Preferred Dividends in Arrears					$ 0	$ 0
Underwritten Offering [Member]
Proceeds from Issuance of Common Stock		$ 45,000,000			$ 0	$ 56,375,000	$ 0
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		5,400,000
Shares Issued, Price Per Share (in dollars per share)		$ 1.25
Proceeds from Issuance of Common Stock		$ 6,750,000
Warrants Issued with Common Stock Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			9,134,615
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.57
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants Exercisable on or Before July 10, 2023 [Member]
Class of Warrant or Right, Outstanding (in shares)					272,250
Warrants Exercisable on or Before January 11, 2024 [Member]
Class of Warrant or Right, Outstanding (in shares)					1,375,000
Warrants Exericsable on or Before October 22, 2025 [Member]
Class of Warrant or Right, Outstanding (in shares)					998,488
Oppenheimer & Co [Member]
Sale of Stock, Commission Rate				3%
Stock Issued During Period, Shares, New Issues (in shares)						0	1,247,232
Shares Issued, Price Per Share (in dollars per share)							$ 0.738
Proceeds from Issuance of Common Stock							$ 920,000
Proceeds from Issuance of Common Stock, Net of Issuance Costs							$ 874,000
[1]Weighted average exercise price per share.

Note 10 - Shareholders' Equity

Note 10 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) - $ / shares		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Warrants issued (in shares)		0	9,134,615
Exercise price (in dollars per share)	[1]	$ 0.70	$ 0.70	$ 0.75	$ 0.75
Warrant [Member]
Warrants issued (in shares)			9,134,615
Exercise price (in dollars per share)			$ 0.57
Expected term (in years) (Year)			5 years
Risk-free rate			0.38%
Volatility			85%
[1]Weighted average exercise price per share.

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Warrant Activity (Details) - $ / shares		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Balance (in shares)		2,645,738	6,080,000
Balance (in dollars per share)	[1]	$ 0.70	$ 0.75
Warrants issued (in shares)		0	9,134,615
Warrants issued (in dollars per share)	[1]	$ 0	$ 0.57
Warrants exercised (in shares)		0	(12,318,877)
Warrants exercised (in dollars per share)		$ 0	$ 0.63	[1]
Warrants expired (in shares)		0	(250,000)
Warrants expired (in dollars per share)		$ 0	$ 0.54	[1]
Warrants exercised (in shares)		0	12,318,877
Warrants expired (in shares)		0	250,000
Balance (in shares)		2,645,738	2,645,738
Balance (in dollars per share)	[1]	$ 0.70	$ 0.70
[1]Weighted average exercise price per share.

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0
Deferred Tax Assets, Valuation Allowance, Percentage	100%	100%
Operating Loss Carryforwards, Total	$ 67,500
Operating Loss Carryforwards, With No Expiration	$ 17,700
Open Tax Year	2020 2021 2022
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 400

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Components (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Fixed assets	$ 9	$ 55
Share-based compensation	525	563
Other accruals	106	49
Asset retirement obligation	134	128
Research credit carryforwards	389	277
Other	7	6
Net operating loss carryforwards	17,904	16,568
Total deferred tax assets	19,074	17,646
Valuation allowance	(19,074)	(17,646)
Total	$ 0	$ 0

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Income Tax Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
U.S. federal statutory income tax rate	21%	21%	21%
Expected income tax benefit	$ (1,522)	$ (711)	$ (724)
Meals and entertainment	14	6	8
Non-deductible penalties	25	22	24
Change in estimate	(9)	28	(58)
Incentive stock options	126	48	0
Research credit	(62)	(52)	11
Change in valuation allowance	1,428	659	739
Income tax expense (benefit)	$ 0	$ 0	$ 0

Note 12 - 401(k) and Profit S_2

Note 12 - 401(k) and Profit Sharing Plan (Details Textual) - Other Pension, Postretirement and Supplemental Plans [Member] - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50%
Defined Contribution Plan, Employer Matching Contribution, First Percent of Contributions Used in Company Match	4%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2%
Liability, Defined Benefit Plan, Total	$ 61,000	$ 0

Note 15 - Concentrations of C_2

Note 15 - Concentrations of Credit and Other Risks (Details Textual) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 26,000	$ 26,000

Note 16 - Quarterly Financial_3

Note 16 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended																12 Months Ended
		Jun. 30, 2022		Mar. 31, 2022		Dec. 31, 2021		Sep. 30, 2021		Jun. 30, 2021		Mar. 31, 2021		Dec. 31, 2020		Sep. 30, 2020		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Net revenue	[1]	$ 2,505		$ 2,910		$ 2,816		$ 2,564		$ 2,710		$ 2,600		$ 2,359		$ 2,384
Gross profit		926	[1]	1,441	[1]	1,220	[1]	1,029	[1]	1,346	[1]	1,362	[1]	1,167	[1]	1,246	[1]	$ 4,616	$ 5,121	$ 5,124
Net loss		$ (2,078)	[1]	$ (1,347)	[1]	$ (1,604)	[1]	$ (2,243)	[1]	$ (1,061)	[1]	$ (745)	[1]	$ (868)	[1]	$ (713)	[1]	$ (7,272)	$ (3,387)	$ (3,446)
Net loss per share – basic and diluted (in dollars per share)		$ (0.01)	[1]	$ (0.01)	[1]	$ (0.01)	[1]	$ (0.02)	[1]	$ (0.01)	[1]	$ (0.01)	[1]	$ (0.01)	[1]	$ (0.01)	[1]	$ (0.05)	$ (0.03)	$ (0.05)
Shares used in basic and diluted per share calculation (in shares)		142,040	[1]	142,040	[1]	141,955	[1]	141,915	[1]	141,673	[1]	122,566	[1]	83,047	[1]	68,898	[1]	141,987	103,841	67,601
[1]Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may be different.

Note 17 - Contracts With Cust_3

Note 17 - Contracts With Customers (Details Textual)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Restocking Fee, Percentage		50%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Prostate Brachytherapy [Member]
Concentration Risk, Percentage	75%	78%	86%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Product and Service, Other [Member]
Concentration Risk, Percentage	25%	22%	14%
Geographic Distribution, Foreign [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Maximum [Member]
Concentration Risk, Percentage	0.10%	0.10%

Note 17 - Contracts With Cust_4

Note 17 - Contracts With Customers - Concentration of Customers (Details) - Customer Concentration Risk [Member]		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Revenue Benchmark [Member] | El Camino, Los Gatos, & Other Facilities [Member]
Concentration risk	[1]	27.90%	25.30%	26.80%
Revenue Benchmark [Member] | GT Medical Technologies, Inc. [Member]
Concentration risk		14.20%	11.30%	10%
Accounts Receivable [Member] | GT Medical Technologies, Inc. [Member]
Concentration risk		10%	10.20%	10%
[1]The head of the single largest physician practice also serves as the Company’s medical director. As the medical director, this physician advises the Company Board of Directors and management, provides technical advice related to product development and research and development, and provides internal training to the Company sales staff and professional training to our sales staff and to other physicians. None of these facilities individually make up more than 10% of our revenue or accounts receivable. On September 20, 2022, we received notice from our medical director of his resignation from such position.

Note 18 - Related Parties (Deta

Note 18 - Related Parties (Details Textual)	12 Months Ended
	Jun. 30, 2022 USD ($)
SphereRx, LLC [Member] | Payments to Suppliers in Russia [Member]
Related Party Transaction, Amounts of Transaction	$ 2,389,787

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Viewpoint Molecular Targeting, Inc. [Member] - Isoray Acquisition Corp. [Member]	Sep. 27, 2022 shares	Sep. 26, 2022
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Per Share (in shares)	3.3212
Business Acquisition, Percentage of Voting Interests Acquired	49%
Number of Board of Directors		4
Number of Board of Directors Appointed by Parent Company	3
Number of Board of Directors Appointed by Acquirer	2
Minimum [Member]
Number of Board of Directors	5